Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record, which for this compound was settled, at least for now, in July 2026.
DSIP has no list price, no prescription route, no insurance pathway and no manufacturer, because it is not approved anywhere, its human studies ended in 1992, and on 24 July 2026 the FDA's advisory committee voted against allowing pharmacies to compound it, the only such rejection that week.12
This page publishes no prices. What follows is what determines the money.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. For DSIP, the substance is known, the quantity is unverified, there is no standard, and the effect is the subject of a 2006 review titled "a still unresolved riddle."3
What Is Actually Being Bought?
A nine-residue peptide, cheap to synthesise, sold at a markup for the word "sleep" in its name. The name was given in 1977 to an effect observed in rabbits.4 The two independent double-blind trials in people found effects that were absent or "of little clinical significance."56 The price is for the name.
Access
Is There a Legal Route?
Not in the United States. DSIP is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It was considered for that list on 24 July 2026, for opioid withdrawal, chronic insomnia and narcolepsy; the FDA proposed against it and the committee voted 7 to 6, with one abstention, to reject it.12 Unlike the six peptides recommended that week, there is no pending decision to wait for.
There is no clinical trial to join. No study of DSIP is registered, and none has been published in people since 1998.7
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. With no approval anywhere there is no covered indication and no billing code attached to one.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What About the Clinics Selling It?
The FDA found integrative neurology clinics, medical concierge services, medical spas and wellness clinics offering DSIP as injectable and intranasal products, and recorded that a compounding pharmacy and its owner had pleaded guilty and been sentenced for unlawful distribution of compounded drugs including DSIP.1 A prescription cannot authorise what federal law does not permit to be compounded, and a clinical setting makes an unlawful supply feel like a medical one without making it one.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, telehealth | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| Nasal spray formulation | Some vendors, clinics | A route with no human data and a multi-dose aqueous bottle with no validated in-use period |
| Bundling into a "sleep stack" with epitalon or others | Clinics, vendors | Other compounds priced together so none is examined alone |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Nine amino acids of unverified purity and sterility, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. It does not buy a molecule that survives injection long enough to matter, because the peptide's half-life is under ten minutes by any route.1
The Spending Decision
What Result Is Being Paid For?
Sleep. That is what the name promises and what every product page sells. The evidence is six intravenous studies from the 1980s in a total of fewer than 60 people, in which one investigator reported benefit against external controls and two independent groups running proper placebo comparisons found little or nothing.1 The FDA's summary: "inconclusive and at best preliminary."1
For the routes actually sold, subcutaneous and nasal, there is no evidence of any kind, positive or negative.
Insomnia has approved treatments with measured effects, and the committee's rejection was partly on that basis. A person paying for DSIP is paying to avoid those, for a peptide whose own researchers are not sure it is a natural sleep signal at all.
What Is the Risk Side of the Ledger?
Probably low, and with one specific question. Intravenous DSIP was well tolerated in the sleep studies; in the 1984 withdrawal study, three of 107 people had serious events including low blood pressure at the first injection.1 The specific question is the mechanism. DSIP acts by triggering enkephalin release, and the FDA noted that "stimulation of the opioid system by emideltide could lead to development of addiction," with no study having looked.1 That is not a finding of addiction. It is a regulator saying nobody has checked, about a product sold for nightly use.
What Should Be Asked Before Paying?
Are you aware the FDA's advisory committee voted against compounding this in July 2026, and on what legal basis are you supplying it?2
Which human study, by this route, measured the outcome you are promising? The honest answer is none.
Can I see a certificate for the batch I will receive, and does its molecular formula actually describe DSIP?
For a nasal spray, what preservative system does it use and what is the in-use period?
Does anyone here earn commission on product sales?
What Would Change This Page
A Trial, or a Reversal
A modern placebo-controlled sleep study by subcutaneous or nasal route would be the first evidence for or against the product as sold. None is registered. The FDA's advisory process has taken the compound up and declined it; a fresh nomination with new data could in principle reopen that, and nothing suggests one is coming.
A Note on the July 2026 Coverage
Because six peptides were recommended that week and DSIP was not, some sellers describe it as having been "reviewed by the FDA" without saying how the review ended. It ended in a vote against.2
Related ONPEPS Coverage
DSIP library entry: the riddle, the 1980s trials and the July 2026 rejection
DSIP sourcing and quality: a ten-minute peptide sold for overnight
FDA peptide news July 2026: the votes, the dissent and what happens next
Sources
US Food and Drug Administration. Emideltide-related bulk drug substances (emideltide (free base) and emideltide acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 24 July 2026. Docket FDA-2025-N-6895. fda.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 7 to 6 vote with one abstention against emideltide. onpeps.com
Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. Open access. pubmed.ncbi.nlm.nih.gov/16539679
Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74(3):1282-1286. Open access. pubmed.ncbi.nlm.nih.gov/265572
Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110. Paywalled. pubmed.ncbi.nlm.nih.gov/3583493
Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. Paywalled. pubmed.ncbi.nlm.nih.gov/1299794
ClinicalTrials.gov. Studies listing delta sleep inducing peptide as an intervention. Registry search returning no relevant studies; checked 16 September 2026. clinicaltrials.gov
Not Medical or Financial Advice
DSIP is not approved for human use in any jurisdiction. Treatment decisions belong with a qualified healthcare provider; insomnia has approved treatments with measured effects. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. Re-verify before relying on anything here.